RT Journal Article
T1 New Vaccines for Chronic Respiratory Patients
A1 Mallah, Narmeen
A1 Dacosta Urbieta, 
A1 Dacosta Urbieta, Ana Isabel
A1 Rivero Calle, Irene
A1 González Barcala, Francisco Javier
A1 Bigoni, Tommaso
A1 Papi, Alberto
A1 Martinón Torres, Federico
K1 Chronic respiratory diseases
K1 Influenza
K1 Pertussis
K1 Pneumococcal disease vaccine
K1 Respiratory syncytial virus
K1 SARS-CoV-2
K1 Vaccine
K1 Monoclonal antibody
AB Chronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations triggered mainly by respiratory infections. Therefore, CRD patients are a prime target for vaccination against infectious agents. In the present manuscript we review the state of the art of available vaccines specifically indicated in patients with CRDs. In addition to pneumococcus, influenza, pertussis, and SARS-CoV-2 vaccines, recently added immunization options like vaccines and monoclonal antibodies against respiratory syncytial virus, are particularly interesting in CRD patients. As new products reach the market, health authorities must be agile in updating immunization recommendations and in the programming of the vaccination of vulnerable populations such as patients with CRDs. Organizational and educational strategies might prove useful to increase vaccine uptake by CRD patients.
PB Elsevier
SN 0300-2896
YR 2024
FD 2024
LK http://hdl.handle.net/10347/34785
UL http://hdl.handle.net/10347/34785
LA eng
NO Archivos de Bronconeumología Volume 60, Issue 9 , September 2024, Pages 565-575
NO This work was supported by consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103; F.M-T), DIAVIR (Instituto de Salud Carlos III [ISCIII]/DTS19/00049/Cofinanciado FEDER; Proyecto de Desarrollo Tecnológico en Salud), Resvi-Omics (Instituto de Salud Carlos III [ISCIII]/PI19/01039/Cofinanciado FEDER), BI-BACVIR (PRIS-3; Agencia de Conocimiento en Salud [ACIS]-Servicio Gallego de Salud [SERGAS]-Xunta de Galicia; Spain), Programa Traslacional COVID-19 (ACIS-Servicio Gallego de Salud [SERGAS]-XUNTA de Galicia; Spain) and Axencia Galega de Innovación  (GAIN; IN607B 2020/08-XUNTA de Galicia; Spain); and ReSVinext (Instituto de Salud Carlos III [ISCIII]/PI16/01569/Cofinanciado FEDER), Enterogen (Instituto de Salud Carlos III [ISCIII]/PI19/01090/Cofinanciado FEDER), OMI-COVI-VAC (PI22/00406/Cofinanced European Regional Development Fund), Grupos de Referencia Competitiva (IIN607A2021/05) and Axencia Galega de Innovación (GAIN; IN845D 2020/23-Xunta de Galicia; Spain).
DS Minerva
RD 28 abr 2026